5. Conclusions
NMSs, dyslipidemia
ADVERSE EVENTS, DYSLIPIDEMIA
In conclusion, our study provides evidence that NMSs have a favorable effect on the reduction of TC, LDL-C, non-HDL-C, and LDL-C to HDL-C ratio compared with a starch placebo in dyslipidemia, although no significant effect was observed in TG, HDL-C, and CIMT. No drug-related adverse events were observed. This fills a gap in the research of nutritional health products. These preliminary results need to be confirmed in future research. Additional studies are essential to elucidate potential underlying mechanisms. The results may represent a novel nutraceutical intervention in dyslipidemia management for patients who do not meet the clinical requirements of statin use.